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Abstract  1 
Administration of dietary doses of the isothiocyanate erucin had no effect on rat 2 
hepatic cytochrome P450 activity or protein levels, but at higher doses a rise in 3 
CYP1A/B1 protein levels was evident. In lung, treatment with erucin, as well as 4 
sulforaphane, failed to modulate cytochrome P450 activities but elevated CYP1A/B1 5 
protein levels. In liver, erucin stimulated quinone reductase activity accompanied by a 6 
rise in protein. Glutathione S-transferase activity was unaffected but GSTα and GSTμ 7 
protein levels increased. In lung, both isothiocyanates increased quinone reductase 8 
paralleled by a rise in protein levels; at the higher dose both isothiocyanates elevated 9 
moderately GSTα levels. Hepatic microsomes converted both isothiocyanates to 10 
metabolites that impaired cytochrome P450 activity, which was antagonised by 11 
reduced glutathione. It may be concluded that erucin may protect against carcinogens 12 
by stimulating the detoxication of quinones but is unlikely to significantly influence 13 
reactive intermediate generation through modulation of cytochrome P450 activity. 14 
  15 
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Introduction 1 
Isothiocyanates comprise a class of phytochemicals present in cruciferous vegetables 2 
and are considered as promising human chemopreventive agents. Epidemiological 3 
studies have revealed the potential of these vegetables to protect against a number of 4 
cancers (1-3), and indeed individual isothiocyanates have been linked, through 5 
epidemiological studies, to lower cancer incidence at a number of sites (4,5). 6 
Experimental evidence in animal models supports a chemopreventive role for these 7 
chemicals; isothiocyanates can antagonise the carcinogenicity of chemicals, including 8 
dietary carcinogens such as polycyclic aromatic hydrocarbons and heterocyclic 9 
amines (6,7). Of importance are recent reports that major metabolites of 10 
isothiocyanates, such as mercapturates, retain the chemopreventive activity (8). 11 
In vegetables isothiocyanates exist in the form of glucosinolates but are 12 
released following exposure to the enzyme myrosinase (β-thioglucoside 13 
glucohydrolase) which comes into contact with these compounds during the 14 
harvesting, chopping and mastication of these vegetables. Moreover, glucosinolates 15 
that progress to the human intestine intact may be metabolised by microbial 16 
myrosinases, further contributing to the release of isothiocyanates (9). Isothiocyanates 17 
are well absorbed and achieve good bioavailability (10). Moreover, experimental 18 
evidence has been recently presented that the glucosinolates of isothiocyanates can 19 
also be absorbed, at least partly, intact (11). 20 
 The chemopreventive mechanism of action of isothiocyanates appears to be 21 
multifactorial, influencing all stages of chemical carcinogenesis, including 22 
impairment of the initiation stage (3,12). Indeed, the consumption of cruciferous 23 
vegetables influenced the metabolism of carcinogenic heterocyclic amines in humans 24 
(13). One of the most extensively studied isothiocyanate is sulforaphane (1-25 
 4
isothiocyanato-4-(methylsulphinyl) butane) (Figure 1), encountered at substantial 1 
concentrations in broccoli, where it exists as the glucosinolate gluroraphanin. Even 2 
when administered at dietary doses, sulforaphane stimulates detoxication enzymes 3 
such as quinone reductase (14), and at higher doses it also enhances the activity of 4 
other deactivating enzyme systems such as glutathione S-transferase (GST) (15). 5 
However, sulforaphane also acts at the post-initiation stages, inducing apoptosis, cell 6 
cycle arrest, inhibition of histone deacetylase and suppressing the conversion of lung 7 
benign tumours to carcinomas in mice (8,16). 8 
Erucin (1-isothiocyanato-4-(methylthio)-butane) (Figure 1) is another 9 
isothiocyanate, structurally related to sulforaphane, being its sulphide analogue. It is 10 
found as the glucosinolate, glucoerucin, and is a major glucosinolate in rocket salad 11 
(roquette; Eruca sativa); moreover there is experimental evidence to suggest that 12 
glucoraphanin can be reduced to glucoerucin by mammalian enzymes (11).  Erucin 13 
itself is also an important metabolite of sulforaphane formed from the reduction of the 14 
sulphinyl group; similarly, sulforaphane is a principal metabolite of erucin, generated 15 
following sulphur oxidation (11,17). Erucin appears to share many of the biological 16 
activities of sulforaphane related to its chemopreventive activity, in many cases being 17 
far more potent (18,19). 18 
 Vegetables are usually cooked by boiling, and this procedure results in 19 
marked loss of glucosinolates which leach into the cooking water, although other 20 
cooking processes such as steaming and microwaving have minimal effects (20). 21 
More importantly, cooking of vegetables denatures myrosinase, the enzyme that 22 
converts the glucosinolates to the active isothiocyanates (21). As a result of these two 23 
effects, the bioavailabilty of isothiocyanates is drastically decreased. Indeed, the 24 
bioavailability of isothiocyanates from broccoli markedly decreased after steaming 25 
 5
(22). An advantage of rocket salad, the major source of the erucin glucosinolate, is 1 
that it is largely consumed raw and, consequently, glucosinolate levels and 2 
myrosinase activity are not adversely affected. As modulation of the xenobiotic-3 
metabolising enzyme systems, resulting in lower availability of the genotoxic 4 
metabolites, is a major mechanism of the anticarcinogenic effects of isothiocyanates, a 5 
study has been undertaken to evaluate the potential of erucin to modulate these 6 
enzyme systems in the liver of rats. Previous studies have been reported in murine 7 
hepatoma cells and in mice treated with erucin by gavage, focussing only on Phase II 8 
enzyme systems (23) but, to our knowledge, this is the first study investigating the 9 
modulation of cytochrome P450 enzymes. Moreover, the ability of erucin to modulate 10 
carcinogen-metabolising enzymes in the lung, a target tissue of isothiocyanates, has 11 
been investigated and compared to sulforaphane. 12 
 13 
Materials and Methods 14 
Sulforaphane and erucin (LKT Laboratories, Minnesota, USA), NADPH, 15 
ethoxyresorufin, pentoxyresorufin, resorufin, 1-chloro-2,4-dinitrobenzene and 1,2-16 
dichloro-4-nitrobenzene, glutathione reductase, peroxidase-linked anti-rabbit and anti-17 
goat antibody raised in rabbits (Sigma Co. Ltd., Poole, Dorset, UK), 7-chloro-4-18 
nitrobenzo-2-oxa-1,3-diazole (Fluka, Buchs SG, Switzerland), 7-benzyloxyquinoline 19 
and 7-hydroxyquinoline (BD Biosciences, California USA), 2-amino-3-20 
methylimidazo-(4,5-f)quinoline (IQ) (Toronto Research Chemicals, Toronto, Canada) 21 
were all purchased. Rat anti-CYP1A1, recognising both CYP1A1 and CYP1A2, anti-22 
CYP1B1, anti-CYP2B and anti-CYP3A2 antibody were obtained from BD 23 
Biochemicals (Oxford, UK), antibodies to human  GST P1-1, A1-1 and M1-1 24 
 6
(Calbiochem, Merck, UK) and antibody to human quinone reductase (abcam 1 
Cambridge, UK) were similarly purchased. 2 
 Male Wistar albino rats (about 180g) were obtained from B&K Universal Ltd 3 
(Hull, East Yorkshire, UK). The animals were housed at 22 ± 2 °C, 30-40% relative 4 
humidity, in an alternating 12-h light:dark cycle with light onset at 07.00 hr. Rats 5 
were randomly divided into four groups, each comprising five animals. One group 6 
served as control, two groups were maintained on drinking water containing 30 or 150 7 
mg/L erucin, corresponding to approximate daily doses of 3 and 15 mg/kg (18.6 and 8 
93.2 μmole/kg) respectively, and the final group was exposed to water containing 9 
sulforaphane (150 mg/L, approximate daily dose of 15 mg/kg, i.e. 88.2 μmole/kg); 10 
animals were maintained on these regimes for 10 days.  At the end of this period, rats 11 
were killed by cervical dislocation, livers and lungs were immediately excised, 12 
homogenised and post-mitochondrial fractions prepared by centrifugation (9000 g for 13 
20 minutes) and stored at -80°C until use. When required, samples were thawed and 14 
resolved to microsomal and cytosolic fractions by centrifugation (105 000g x 1 hour). 15 
The dealkylations of methoxy- (24), ethoxy- (25), pentoxy-resorufin (26) and 7-16 
benzyloxyquinoline (27) were determined using the microsomal fraction. The 17 
following assays were performed in the cytosol; quinone reductase using MTT [3-(4,-18 
5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide] as substrate (28), 19 
glutathione S-transferase activity using as accepting substrates 1-chloro-2,4-20 
dinitrobenzene, 1,2-dichloro-4-nitrobenzene (29) and 7-chloro-4-nitrobenzo-2-oxa-21 
1,3-diazole (30), and total glutathione (31). Protein concentration was determined in 22 
both fractions using bovine serum albumin as standard (32). Finally, in order to 23 
determine changes in enzyme protein expression, hepatic and pulmonary microsomal 24 
proteins from pooled animals were resolved by SDS-PAGE before being transferred 25 
 7
electrophoretically to Hybond-P polyvinylidene difluoride membrane. Immunoblot 1 
analysis was carried out using antibodies to cytochrome P450 or Phase II enzymes, 2 
followed by the appropriate peroxidase-labelled secondary antibody. Molecular 3 
markers were always run concurrently. Immunoblots were quantitated by 4 
densitometry using the GeneTool software (Syngene Corporation, Cambridge, UK).  5 
To induce the hepatic CYP1A and CYP2B subfamilies of cytochrome P450, 6 
rats were treated with a single intraperitoneal dose of Aroclor-1254 (500 mg/kg), the 7 
animals being killed on the 5th day following administration. In studies aimed at 8 
establishing the effect of erucin (25 M) on the in vitro O-dealkylation of 9 
ethoxyresorufin, microsomes from Aroclor-1254-induced animals were incubated 10 
with erucin or sulforaphane in the presence of NADPH for various periods of time, 11 
and reaction was initiated with the addition of the substrate. In studies aimed at 12 
studying the concentration-dependent effects, microsomes from Aroclor-1254-13 
induced rats were incubated with a series of concentrations of erucin or sulforaphane 14 
in the presence of NADPH for 30min, and reaction was initiated with the addition of 15 
the substrate. 16 
Mutagenic activity induced by IQ was monitored using the Ames mutagenicity 17 
assay (33) in the presence of an activation system containing 10% (v/v) hepatic S9 18 
preparations from control, erucin- and Aroclor 1254-treated rats, and employing 19 
Salmonella typhimurium YG1024 as the indicator strain. 20 
 Statistical evaluation was carried out employing Student’s t-test.  21 
 22 
 23 
 24 
 25 
 8
Results 1 
Intake of neither erucin nor sulforaphane influenced animal body weight gain, and 2 
water consumption did not differ between control and isothiocyanate-treated animals 3 
(results not shown). 4 
 Treatment of rats with erucin failed to modulate the hepatic dealkylations of 5 
methoxy-, ethoxy- or pentoxyresorufin, catalysed selectively by CYP1A2, CYP1A1 6 
and CYP2B respectively, and of 7-benzoyloxyquinoline catalysed by CYP3A 7 
(Table1). Immunoblot analysis employing antibodies to rat CYP1A1 recognised a 8 
single band, presumably CYP1A2, whose levels were modestly (30%) elevated by the 9 
higher dose of erucin (Figure 2A) A single band was also recognised by the 10 
antibodies to CYP1B1, and its expression increased (90%) following treatment of the 11 
animals with the higher dose of erucin (Figure 2A). Treatment with erucin failed to 12 
modulate the levels of the single band detected by anti-rat CYP2B1 and CYP3A2 13 
antibodies (Figure 2A). 14 
Cytosolic glutathione S-transferase activity in the liver, determined using 7-15 
chloro-4-nitrobenzo-2-oxa-1,3-diazole, 1-chloro-2,4-dinitrobenzene or 1,2-dichloro-4-16 
nitrobenzene as substrates, and total glutathione levels were unaffected by the erucin 17 
treatment, whereas quinone reductase activity was stimulated at both dose levels 18 
(Table 1). Immunoblot analysis indicated that erucin, at both dose levels, up-19 
regulated the levels of GSTα and GSTμ, as well as quinone reductase, but GST was 20 
unaffected (Figure 2B).  21 
In lung, neither isothiocyanate modulated the O-dealkylation of the two 22 
alkoxyresorufins (Table 2); 7-benzyloxyquinoline demethylase was not detectable in 23 
this tissue. Immunoblot studies revealed that erucin, at both doses, as well as 24 
sulforaphane elevated pulmonary CYP1A1 protein levels (Figure 3A). Similarly, the 25 
 9
higher erucin dose and sulforaphane increased the band recognised by antibody to 1 
CYP1B1 antibody by 80 and 70% respectively (Figure 3A). No changes were evident 2 
in the case of CYP2B1 or CYP3A2. Glutathione S-transferase activity, whether 3 
monitored with 1-chloro-2,4-dinitrobenzene or 7-chloro-4-nitrobenzo-2-oxa-1,3-4 
diazole, and total glutathione levels were not influenced by the isothiocyanate 5 
treatment. Quinone reductase activity, which was higher in the lung compared with 6 
the liver, was clearly elevated by the treatments  with erucin or sulforaphane (Table 7 
2). The increase in quinone reductase activity was paralleled by a similar rise in 8 
protein levels determined by immunoblot, being 165 and 150% higher in the animals 9 
treated with the high erucin dose and sulforaphane respectively, in comparison with 10 
controls (Figure 3B). Erucin, at the higher dose, similar to sulforaphane, raised the 11 
levels of GSTα by 25-30% whereas GST and GSTμ were unaffected (Figure 2B).  12 
 Both isothiocyanates, following pre-incubation in the presence of NADPH, 13 
suppressed the hepatic O-deethylation of ethoxyresorufin in Aroclor 1254-induced 14 
hepatic microsomes to a similar degree (Figures 4A and 4B); extent of inhibition was 15 
time-dependent with respect to pre-incubation time (Figure 4C). Reduced glutathione 16 
prevented the suppression of O-deethylation of ethoxyresorufin following pre-17 
incubation with the isothiocyanate (Figure 5); oxidised glutathione had no effect 18 
(results not shown). Finally, in the absence of pre-incubation, neither compound, at 19 
least up to a concentration of 25μM, influenced the O-deethylation of ethoxyresorufin 20 
(results not shown).  21 
 The bioactivation of the heterocyclic amine IQ to genotoxic intermediates in 22 
the Ames test was determined in the presence of hepatic post-mitochondrial 23 
preparations from control, erucin- and sulforaphane-pretreated rats.  A concentration-24 
dependent mutagenic response was evident in the presence of all activation systems; 25 
 10
treatment with either isothiocyanate caused a modest decrease in mutagenic response 1 
(Figure 6). 2 
 3 
Discussion 4 
One of the major mechanisms through which isothiocyanates are believed to elicit 5 
their anticarcinogenic effects is by limiting the amount of genotoxic metabolites of 6 
chemical carcinogens by either stimulating their detoxication and/or impairing their 7 
generation (3). Consequently, the aim of this study was to evaluate the potential of the 8 
isothiocyanate erucin to modulate glutathione S-transferase and quinone reductase, 9 
two pivotal enzymes in the detoxication of reactive intermediates and prevention of 10 
oxidative stress, and cytochromes P450, the most important enzyme in the generation 11 
of these intermediates; studies were conducted in the liver, the principal site of 12 
metabolism, and lung, a target tissue for the anticarcinogenic effect of isothiocyanates 13 
(9). The effects of erucin on pulmonary enzymes were compared with those of 14 
sulforaphane, as the influence of the latter has not been studied in this tissue following 15 
exposure to dietary doses. It has been established that sulforaphane is metabolised to 16 
erucin in the rat, and erucin can be readily formed from the reduction of sulforaphane 17 
(11,17).  18 
 Previous studies in mice have indicated the potential of erucin and 19 
sulforaphane, at least at high doses administered by gavage, to stimulate quinone 20 
reductase and glutathione S-transferase activities in the liver and other tissues (23), 21 
but to our knowledge this is the first study evaluating the potential of this 22 
isothiocyanate to modulate cytochrome P450 enzymes. Both isothiocyanates were 23 
given to rats in the drinking water, and a dose was employed that corresponds to the 24 
human intake. Since, to our knowledge, the human consumption levels of erucin or 25 
 11
glucoerucin have not been defined, the doses employed in these studies was based on 1 
the consumption of sulforaphane, a structurally similar isothiocyanate. A 250g serving 2 
of fresh broccoli will release 93-187 mg of sulforaphane (34), so that the intake for a 3 
70 kg individual would be 1.3-2.7 mg/kg. The lower dose of erucin employed in the 4 
current study of approximately 3 mg/kg represents such dietary level of intake. 5 
None of the cytochrome P450 activities studied were modulated by treatment 6 
with erucin in the liver or lung, or with sulforaphane in the lung. In the lung, however, 7 
both compounds elevated the levels of the band recognised by the antibody to 8 
CYP1A1. CYP1B1 could not be monitored at the activity level as a selective substrate 9 
is not available, but immunoblot analysis indicated that treatment with erucin, at the 10 
higher dose, elevated the levels of this enzyme in the liver. In the lung, both 11 
isothiocyanates led to an increase in the single band detected by the CYP1B1 12 
antibody. Neither compound had any effect on CYP2B or CYP3A2 protein levels. 13 
Up-regulation of the CYP1 family, albeit at the mRNA level, has been reported 14 
following exposure of HepG2 cells to 4-methylthio-3-butenyl isothiocyanate (35). 15 
Erucin, at both dose levels, gave rise to a significant increase in hepatic 16 
quinone reductase activity as previously described for sulforaphane (14). For both 17 
tissues, Western blot analysis indicated that this was due to increased cytosolic 18 
concentration of quinone reductase. Contrary to the present observations, exposure of 19 
rats to phenethyl isothiocyanate failed to enhance this activity in the lung (36), 20 
highlighting the importance of the side chain; it is of interest that sulforaphane and 21 
erucin have an aliphatic side chain whereas in the case of phenethyl isothiocyanate it 22 
is aromatic. Glutathione S-transferase activity was monitored using three substrates; 23 
1-chloro-2,4-dinitrobenzene is a substrate for a number of the cytosolic transferases 24 
(37). The much higher activity in the liver compared with the lung reflects the higher 25 
 12
capacity of the former tissue to detoxicate electrophiles. Both compounds failed to 1 
influence activity in lung and, similarly, in the liver erucin had no effect. 1,2-2 
Dichloro-4-nitrobenzene is a substrate associated with the μ-family, but no activity 3 
was detectable in lung a as a result of poor expression in this tissue (37). Hepatic 4 
activity was not influenced by erucin treatment although a rise in protein levels was 5 
clearly visible. Finally, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole has been reported to 6 
be selective for the α-class (30), and the very low activity in the lung demonstrates the 7 
poor expression of this class in this tissue (37). A rise in GST activity was not seen 8 
with any of the three accepting substrates studied, whereas GSTα and GSTμ were up-9 
regulated at the protein level. Similarly, in lung no change in activity was manifested 10 
by treatment with either isothiocyanate, but GSTα levels increased, GST was not 11 
modulated by either isothiocyanate in either tissue. Thus, the effects of 12 
isothiocyanates on the GST system are both compound and tissue specific. 13 
As isothiocyanates, with either aliphatic or aromatic side chain, can be 14 
metabolically converted to intermediates that cause cytochrome P450 inhibition, the 15 
ability of erucin to act as a mechanism-based inhibitor was evaluated and compared to 16 
sulforaphane. The two isothiocyanates did not differ in their ability to suppress, in a 17 
time-dependent manner, the O-deethylation of ethoxyresorufin. The fact that 18 
inhibition was prevented by reduced, but not oxidised, glutathione concords with the 19 
generation of an electrophilic metabolite(s). A more reactive isocyanate, derived from 20 
the cytochrome P450-mediated isothiocyanate oxidation (38), has been postulated as 21 
the possible entity that interacts and inactivates cytochromes P450. Isocyanates are 22 
known to be capable of modifying proteins. Indeed, α-naphthyliosothiocyanate was 23 
converted by rat liver microsomes, in the presence of NADPH, to metabolites that 24 
bound irreversibly to microsomal proteins (39).  25 
 13
In order to assess whether the erucin treatment had any impact on the ability of 1 
liver microsomes to bioactivate chemical carcinogens, the metabolic conversion of the 2 
heterocyclic amine 2-amino-3-methylimidazo-(4,5-f)quinoline (IQ) to mutagens was 3 
investigated using the Ames mutagenicity assay. This compound was used as model 4 
carcinogen as previous studies showed that sulforaphane inhibits the genotoxicity and 5 
DNA-adduct formation of heterocyclic amines in cell cultures in vitro (40,41). Erucin 6 
treatment caused a modest decrease in the bioactivation of IQ but no clear 7 
concentration-dependent effect was evident. Sulforaphane had a similar, modest effect 8 
as we previously reported (14). 9 
In summary, the present studies have demonstrated that following intake of 10 
erucin, at a dose corresponding to human intake, the only enzyme modulated of those 11 
studied was quinone reductase; an increase was seen in both liver and lung. No 12 
cytochrome P450 enzyme was perturbed by the erucin treatment implying that 13 
attenuated generation of genotoxic intermediates is unlikely to be a chemopreventive 14 
mechanism at dietary dose levels. These observations allow us to conclude that erucin 15 
may exert a chemopreventive effect by affording protection against the 16 
carcinogenicity of quinones, such as those formed by the oxidation of polycyclic 17 
aromatic hydrocarbons. At higher doses, which may be achieved by the consumption 18 
of dietary supplements, the expression of other enzymes was modulated, at least at the 19 
protein level. In general, no marked differences were observed between erucin and 20 
sulforaphane. However, as the major source of erucin is rocket salad which is largely 21 
consumed uncooked, it may prove a more promising chemopreventive agent than 22 
sulforaphane as it is likely to achieve a higher bioavailability. The principal sources of 23 
sulforaphane are vegetables which are consumed cooked, resulting in lower 24 
conversion of the glucosinolate to the isothiocyanate. Finally, to our knowledge, this 25 
 14
is the first paper to report the ability of dietary isothiocyanates to up-regulate CYP1B1 1 
expression in the liver and lung. 2 
 3 
 4 
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Legends to figures 1 
Figure 1: Chemical structures of erucin and sulforaphane 2 
Figure 2: Modulation of rat hepatic cytochrome P450 and Phase II enzymes by 3 
treatment with erucin 4 
 5 
Figure 3: Modulation of rat pulmonary cytochrome P450 and Phase II enzymes 6 
by treatment with erucin and sulforaphane 7 
 8 
Figure 4: Effect of pre-incubation on the inhibition of the hepatic O-deethylation 9 
of ethoxyresorufin by erucin and sulforaphane. 10 
 11 
Results are presented as mean  SD of triplicate determinations. 12 
*P<0.05; **P<0.01; ***P<0.001 13 
 14 
Figure 5: Effect of glutathione on the erucin- and sulforaphane-mediated 15 
inhibition of the O-deethylation of ethoxyresorufin 16 
 17 
Results are presented as mean  SD of triplicate determinations. 18 
*P<0.05; **P<0.01; ***P<0.001 19 
 20 
Figure 6: Effect of erucin treatment on the activation of IQ to mutagenic 21 
intermediates in the Ames test. 22 
 23 
Aroclor 1254-induced activation system (positive control) elicited a mutagenic 24 
response of 7562 ± 1240 revertants/plate at an IQ concentration of 1000 ng/plate. The 25 
spontaneous reversion rate of 48 ± 8 has already been subtracted. Results are 26 
presented as mean  SD for triplicate plates. 27 
*P<0.05; **P<0.01 28 
 29 
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Table 1: Effect of treatment with erucin on rat hepatic cytochrome P450 and phase II 4 
enzyme activitiesa 5 
 6 
 7 
Enzyme activity Control Erucin (Low 
dose) 
Erucin (High dose) 
Methoxyresorufin O-
demethylase 
(pmol/min/mg protein) 
23 ± 6 20 ± 2 16 ± 6 
Ethoxyresorufin O-
deethylase 
(pmol/min/mg protein) 
30 ± 7 24 ± 3 20 ± 9 
Pentoxyresorufin O-
depentylase 
(pmol/min/mg protein) 
3.3 ± 0.7 2.5 ± 0.5 3.1 ± 0.7 
Benzyloxyquinoline O-
debenzylase 
(pmol/min/mg protein) 
327 ± 84 369 ± 60 291 ± 63 
Quinone reductase 
(nmol/min/mg protein) 
679 ± 298 1074 ± 125** 1270 ± 130*** 
Glutathione S-transferase 
(1-chloro-2,4-
dinitrobenzene) 
(nmol/min/mg protein) 
2137 ± 190 2181 ± 258 1947 ± 236 
Glutathione S-transferase 
(7-chloro-4-nitrobenzo-2-
oxa-1,3-diazole) 
(nmol/min/mg protein) 
463 ± 112 414 ± 116 477 ± 116 
Glutathione S-transferase 
(1,2-dichloro-4-
nitrobenzene) 
(nmol/min/mg protein) 
73 ± 5 67 ± 11 66 ± 11 
Total glutathione (mM) 5.13 ± 0.67 4.56 ± 0.51 4.76 ± 0.56 
a Results are presented as mean ± SD for five rats. ** Significantly different compared 8 
with control (**P<0.01). *** Significantly different compared with control (P<0.001). 9 
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 13 
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Table 2: Effect of treatment with erucin and sulforaphane on rat pulmonary 4 
cytochrome P450 and phase II enzyme activitiesa 5 
 6 
Rats were maintained on erucin- or sulforaphane-supplemented diets for 10 days. 7 
Results are presented as mean ± SD for five rats.  8 
*P<0.05; **P<0.01 9 
Enzyme activity Control Erucin 
(Low dose) 
Erucin 
(High dose) 
Sulforaphane
Ethoxyresorufin O-
deethylase 
(pmol/min/mg protein) 
0.91 ± 0.35 0.71 ± 0.21 0.98 ± 0.27 0.71 ± 0.29 
Pentoxyresorufin O-
depentylase 
(pmol/min/mg protein) 
3.26 ± 0.70 2.53 ± 0.50 3.09 ± 0.69 2.59 ± 1.02 
Quinone reductase 
(nmol/min/mg protein) 
1288 ± 298 1709 ± 238* 2526 ± 40** 2775 ± 497** 
Glutathione S-transferase 
(1-chloro-2,4-
dinitrobenzene) 
(nmol/min/mg protein) 
24 ± 5 23 ± 4 32 ± 6 31 ± 6 
Glutathione S-transferase 
(7-chloro-4-nitrobenzo-2-
oxa-1,3-diazole) 
(nmol/min/mg protein) 
2.84 ± 0.58 2.16 ± 0.68 3.45 ± 0.61 3.79 ± 0.78 
Total glutathione (mM) 0.82 ± 0.28 0.66 ± 0.08 0.82 ± 0.22 0.79 ± 0.09 
a Results are presented as mean ± SD for five rats. * Significantly different compared 10 
with control (**P<0.05). ** Significantly different compared with control (P<0.01). 11 
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